Summit Therapeutics plc Holding(s) In Company
2020年1月20日 - 11:15PM
RNSを含む英国規制内ニュース (英語)
TIDMSUMM
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the
relevant issuer and to the FCA in Microsoft Word format
if possible)(i)
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
1a. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are attached(ii) Summit Therapeutics PLC
: Sedol BN40HZ0
------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer
(please mark with an "X" if appropriate)
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Non-UK issuer
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------
2. Reason for the notification (please mark the appropriate
box or boxes with an "X")
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------
An acquisition or disposal of financial instruments
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------
An event changing the breakdown of voting rights
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------
Other (please specify)(iii) :
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------
3. Details of person subject to the notification obligation(iv)
Name
City and country of registered office (if applicable)
4. Full name of shareholder(s) (if different from
3.)(v)
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Name Robert W. Duggan
------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
City and country of registered office (if applicable)
------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
5. Date on which the threshold was crossed or reached(vi)
: 14/01/2020
------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 17/01
------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
7. Total positions of person(s) subject to the notification
obligation
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
% of voting rights attached to shares (total of 8. % of voting rights through financial instruments Total of both in
A) (total of 8.B 1 + 8.B 2) % (8.A + 8.B) Total number of voting rights of issuer(vii)
--------------------------------------------------- -------------------------------------------------- ------------------------------------------------ ---------------- --------------------------------------------
Resulting situation on the date on which threshold
was crossed or reached 39.55% 23.31% 62.86% 335,873,208
--------------------------------------------------- -------------------------------------------------- ------------------------------------------------ ---------------- --------------------------------------------
Position of previous notification (if
applicable) 49.47% 23.31% 72.78%
--------------------------------------------------- -------------------------------------------------- ------------------------------------------------ ---------------- --------------------------------------------
8. Notified details of the resulting situation on
the date on which the threshold was crossed or reached(viii)
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Class/type of
shares
ISIN code (if possible) Number of voting rights(ix) % of voting rights
--------------------------
Direct Indirect Direct Indirect
(Art 9 of Directive 2004/109/EC) (DTR5.1) (Art 10 of Directive 2004/109/EC) (DTR5.2.1) (Art 9 of Directive 2004/109/EC) (DTR5.1) (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
------------------------- ------------------------------------------ --------------------------------------------- ----------------------------------------------------- ---------------------------------------------
GB00BN40HZ01 132,835,180 39.55%
-------------------------- ------------------------------------------ --------------------------------------------- ----------------------------------------------------- ---------------------------------------------
SUBTOTAL 8. A 132,835,180 39.55%
-------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a)
of Directive 2004/109/EC (DTR5.3.1.1 (a))
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Number of voting rights that may be acquired if the
Type of financial Expiration Exercise/ instrument is
instrument date(x) Conversion Period(xi) exercised/converted. % of voting rights
-------------------------- ------------------------------------------ --------------------------------------------- ----------------------------------------------------- ---------------------------------------------
American Depositary Shares
(ADS) n/a n/a 78,288,205 23.31%
-------------------------- ------------------------------------------ --------------------------------------------- ----------------------------------------------------- ---------------------------------------------
SUBTOTAL 8. B 1 78,288,205 23.31%
--------------------------------------------- ----------------------------------------------------- ---------------------------------------------
B 2: Financial Instruments with similar economic effect
according to Art. 13(1)(b) of Directive 2004/109/EC
(DTR5.3.1.1 (b))
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Conversion Physical or cash Number of voting rights % of voting rights
instrument date(x) Period (xi) settlement(xii)
------------------------- ------------------------------------------- --------------------------------------------- ------------------ --------------------------------- ---------------------------------------------
SUBTOTAL 8.B.2
------------------ --------------------------------- ---------------------------------------------
9. Information in relation to the person subject to
the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not X
controlled by any natural person or legal entity and
does not control any other undertaking(s) holding
directly or indirectly an interest in the (underlying)
issuer(xiii)
Full chain of controlled undertakings through which
the voting rights and/or the
financial instruments are effectively held starting
with the ultimate controlling natural person or legal
entity(xiv) (please add additional rows as necessary)
-------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------
Name(xv) % of voting rights if it equals or is higher than % of voting rights through financial instruments if Total of both if it equals or is higher than the notifiable
the notifiable threshold it equals or is higher than the notifiable threshold threshold
-------- ------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------
10. In case of proxy voting, please identify:
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Name of the proxy holder
----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
The number and % of voting rights held
----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
The date until which the voting rights will be held
----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
11. Additional information(xvi)
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Place of completion Florida, United States of America
------------------- ---------------------------------
Date of completion 16/01/2020
------------------- ---------------------------------
(END) Dow Jones Newswires
January 20, 2020 09:15 ET (14:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
過去 株価チャート
から 12 2024 まで 1 2025
Summit Therapeutics (LSE:SUMM)
過去 株価チャート
から 1 2024 まで 1 2025
Real-Time news about Summit Therapeutics Plc (ロンドン証券取引所): 0 recent articles
その他のSummit Therapeutics Plcニュース記事